IDH1 and glioblastoma: The WHO 2016 molecular subgrouping into IDH-wild-type and IDH-mutant glioblastoma emphasizes a significantly longer survival for the IDH-mutant subgroup, due to a slower tumor growth rate, and is reflected in a more insidious onset [21].